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Abstract
Stem cell therapies are successfully used in various fields of medicine. This new 
approach of research is also expanding in ophthalmology. Huge investments, 
resources and important clinical trials have been performed in stem cell research 
and in potential therapies. In recent years, great strides have been made in genetic 
research, which permitted and enhanced the differentiation of stem cells. 
Moreover, the possibility of exploiting stem cells from other districts (such as 
adipose, dental pulp, bone marrow stem cells, etc.) for the treatment of ophthalmic 
diseases, renders this topic fascinating. Furthermore, great strides have been made 
in biomedical engineering, which have proposed new materials and three-
dimensional structures useful for cell therapy of the eye. The encouraging results 
obtained on clinical trials conducted on animals have given a significant boost in 
the creation of study protocols also in humans. Results are limited to date, but 
clinical trials continue to evolve. Our attention is centered on the literature 
reported over the past 20 years, considering animal (the most represented in 
literature) and human clinical trials, which are limiting. The aim of our review is 
to present a brief overview of the main types of treatments based on stem cells in 
the field of ophthalmic pathologies.
Key Words: Stem cells; Multipotent mesenchymal cells; Adipose stem cells; Novel 
therapies; Eye pathology; Cornea; Cell therapies; New materials
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Core Tip: Stem cell therapies have shown great potential in ophthalmopathies. 
Interesting results have arisen in the treatment of ocular surface diseases and for their 
neuroprotective effect. Stem cells can be transplanted, injected or topically applied. 
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The main goals of treatments include preventing vision loss, restoring sight, recreating 
the connections with the central nervous system, and regenerating eye tissues. Recent 
discoveries have permitted the use of stem cells taken from other districts. From 
literature analysis, it is clear that stem cells can provide a potentially successful 
solution; however, ethical issues, costs and possible long term side effects limit the 
current use.
Citation: Miotti G, Parodi PC, Zeppieri M. Stem cell therapy in ocular pathologies in the past 20 




Numerous studies in scientific medical literature continually show that cell therapy 
tends to be an effective alternative and innovative method to regenerate damaged 
tissue[1]. In the last decades, studies have shown that stem cell therapies can bring 
substantial benefits to patients suffering from a wide range of diseases and injuries[2]. 
For this reason, huge investments, resources and important clinical trials have been 
performed in stem cell research and potential therapies based on stem cells. In these 
past years, there has been a continuing expansion in the number and types of stem 
cells assessed for potential treatment use. Stem cells are now being used in various 
fields of medicine, ranging from hematology to cardiology, in addition to neurology, 
plastic surgery, dentistry, etc.[3-5]. Although literature has reported limited success to 
date, clinical trials continue to evolve as our understanding enhances regarding the 
physiology and mechanisms underlying potential healing benefits behind stem cells. 
Recent advancements in regenerative medicine have also considered the use of stem 
cells for cellular repair and regeneration[6].
Stem cell therapies have shown great potential in numerous studies reported in 
literature concerning injuries and diseases of the eye[3]. This progress is a result of 
several factors, including the relatively small numbers of cells required, easy access-
ibility for surgery and straightforward assessment and visualization of grafts. 
Numerous types of cells have been used in clinical trials for the eye[2]. Research on 
stem cell therapies has been applied to almost all parts of the eye.
Based on our preliminary animal experiments regarding stem cells therapies in 
corneal healing[3,7], and the growing number of studies that show great clinical 
potentials of stem cells for this therapeutic approach, we decided to assess the 
literature reported in the last 20 years. Considering that the number of studies 
reported in literature since 2000 is immense, and our experience in this field is limiting, 
we do not intend to provide an exhaustive meta-analysis, but a quick overview of the 
use of stem cells for ophthalmology treatment; thus, we apologize in advance if 
opinion leaders and experts in this field of study have not been cited in our paper. The 
aim of our review is to present a brief overview of the main types of treatments based 
on stem cells in the field of ophthalmic pathologies, by briefly addressing the what, 
why, which, how, when and where of this issue. We have tried to concentrate or 
review on pertinent human studies; however, considering most of the literature to date 
tends to be based on animal experimentation, mention has also been made regarding 
this vast body of literature.
MATERIALS AND METHODS
We conducted a search of the literature published between January 1, 2000, to 
December 20, 2020, using MEDLINE (PubMed). The database was first searched using 
the key words “stem, cell and eye”, in which 7486 studies were found. We considered 
only studies in English and those referring to humans, thus reducing the count to 3941. 
The reference lists of all retrieved articles were scanned to identify additional relevant 
studies. We then considered only articles based on “stem cells therapy” (2194 papers), 
and we excluded “case reports”, “case series”, “conference papers”, “letters” and “in 
vitro” (1179 articles). Results were then divided and sorted by when/where stem cells 
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were used, which included: Ocular surface; corneal epithelium, stroma, endothelium, 
limbus; trabecular meshwork; lens; optic nerve; retina. The details regarding the 
selection of papers considered in the manuscript are listed in Figure 1.
Only articles with abstracts were considered (1148 articles). After a selection by title 
and abstract, 185 articles were analyzed. A quality score was calculated for each article 
using a checklist from the American Society of Plastic Surgeons guidelines for 
therapeutic studies[7]. Each study was appraised by at least two reviewers (GM and 
MZ), and rating decisions were based on the consensus of the reviewing authors. A 
summary of the most significant studies and conclusions is reported in Tables 1 and 2.
What are stem cells
In brief, stem cells are undifferentiated cells that are present in the embryonic, fetal 
and adult stages of life and give rise to differentiated cells, which are the building 
blocks of tissue and organs. In the post-natal and adult stages of life, tissue-specific 
stem cells are found in differentiated organs and are instrumental in repair following 
injury to the organ. The main characteristics of stem cells are self-renewal (the ability 
to proliferate extensively), clonality (usually arising from a single cell) and potency 
(the ability to differentiate into different cell types)[8].
Stem cells can be classified as totipotent (zygote), pluripotent [embryonic stem cells 
(ESCs) and induced pluripotent stem cells (iPSCs)], multipotent [mesenchymal stem 
cells (MSCs)] and oligopotent. Totipotent cells form embryonic and extra-embryonic 
tissues. Pluripotent cells form all three germ layers, while multipotent cells generate 
cells limited to one germ layer.
The human body develops from the zygote and blastocyst from which ESCs are 
derived into germ layers endoderm, mesoderm and ectoderm. Specific organs arise 
from germ layers. Some of the progenitor cells that have contributed to organ 
formation do not terminally differentiate but are retained as tissue stem cells and can 
be found in bone marrow, bone, blood, muscle, liver, brain, adipose tissue, skin and 
gastrointestinal tract[9]. The tissue stem cells may be called progenitor cells since they 
give rise to terminally differentiated and specialized cells of the tissue or organ. These 
cells may be dormant within tissues; however, have the ability to proliferate under 
circumstances of injury and repair[10]. The dynamics of tissue stem cells or progenitor 
cells varies from tissue to tissue. In bone marrow, liver, lung and gut, for example, 
stem cells regularly proliferate to supplement cells during normal turnover of cells or 
tissue injury. In other organs, however, like pancreas, heart or nervous system, stem 
cells proliferate to replace damaged cells following injury[11,12].
Why use stem cells in ocular diseases 
The human eye is a remarkable structure produced from the coordinated development 
of multiple tissues. It is the result of a combination of tissues deriving from neuroecto-
dermal (e.g., retina), ectodermal (e.g., lens and cornea) and mesodermal lines. Diseases 
and injuries that compromise the function of any of these major ocular tissues can lead 
to blindness[13,14]. Considering the fundamental importance and influence on quality 
of life of sight, research has invested enormous resources and studies towards the 
search for new therapies to prevent and treat ocular disorders. There is a notable 
history of trail-blazing work in ocular medicine, exemplified by tissue transplantation, 
the use of laser therapy, the recent gene-therapy and cell therapy[14]. Due to burden of 
eye disease, and its relative ease of accessibility, the eye is a prime target for stem cell 
transplantation therapies, in which complications tend to be rare (e.g., overgrowth and 
tumor formation)[15]. In addition, advanced methods currently exist to examine easily 
and thoroughly assess the clinical results of eye transplant therapies. Modern 
technology is readily available to provide a non-invasive quantifiable visualization of 
most structures of the eye, and visual functions can routinely be assessed rapidly, 
quantitatively and accurately.
Which stem cells can be considered for treatment in ophthalmology
Human pluripotent stem cells: ESCs and iPSCs: Human pluripotent stem cells 
(hPSCs) have been considered promising sources for regenerating damaged tissues 
and organs because of their ability to differentiate into cells from three embryonic 
germ layers[16]. These cells can also be maintained in an undifferentiated state for a 
prolonged period in culture[8]. There are numerous scientific studies regarding 
therapy with hPSCs, specifically, in the form of iPSCs. Several studies have reported 
the use of iPSCs in retinal degenerative pathologies[2,17,18]. hPSCs have the greatest 
potential for cell replacement and can be successfully pre-differentiated prior to 
transplantation in the eye. iPSCs are pluripotent stem cells generated from somatic 
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Table 1 Clinical trials in ocular diseases
Ophthalmic disease Ref. Stem cells used In animals or humans Conclusions
Ocular surface, cornea 
and limbus
Kenyon and Tseng[52], 
1989
Limbal tissue autograft 
transplantation (LSCs)
Humans Patients have consistently shown improved visual 
acuity, rapid surface healing, stable epithelial 
adhesion without recurrent erosion, arrest or 
regression of corneal neovascularization
Lindberg et al[53], 1993 LSCs Humans Corneal epithelial stem cells are located in the 
limbus and indicate that cultured autologous 
limbal cells may function as grafts to permanently 
restore the corneal epithelium after severe ocular 
surface injury
Ma et al[54], 2006 MSCs like LSCs on 
amniotic membrane
Animals Therapeutic effect due to the inhibition of 
inflammation and neovascularization
Kwitko et al[57], 1995 Conjunctival autograft 
transplantation
Humans Conjunctival transplantation proved to be an 
adequate method of treating severe bilateral 
surface disorders, with minimal complications
Croasdale et al[58], 1999 Keratolimbal allograft Humans KLAL transplantation for patients with severe 
ocular-surface disease is an important 
management option
Tsai et al[59], 2000 Limbal epithelial cells Humans By 1 mo, the ocular surface was covered with 
corneal epithelium, and the clarity of the cornea 
was improved in 83% of patients
Sangwan et al[60], 2012 Limbal tissue Humans After surgery, a completely epithelialized, 
avascular and stable corneal surface was seen in 
all recipient eyes by 6 wk
Kushnerev et al[61], 2016 Dental pulp stem cells Animals Dental pulp stem cells were successfully isolated, 
labeled, and delivered to the corneal surface
Chan et al[66], 2013 iPSCs Animals hES cells can be induced to differentiate into 
keratocytes in vitro. Pluripotent stem cells may 
provide a renewable source of material for 
development of treatment of corneal stromal 
opacities
Susaimanickam et al[67], 
2017
iPSCs Animals PSC-derived corneal epithelial cells offer an 
alternative tissue source for regenerating different 
layers of the cornea and eliminate the need for 
complicated cell enrichment procedures
Zeppier et al[3], 2017 MSCs Animals Better corneal repair in epithelium and stromal 
layers in stem cell treated eyes
Reinshagen et al[68], 2011 BM-MSCs Animals BM-MSCs could differentiate into cornel epithelial 
like cells in vivo in rat damaged corneas
Gu et al[70], 2009 BM-MSCs Animals BM-MSCs could differentiate into cornel epithelial 
like cells
Beyazyildiz et al[46], 2014 MSCs Animals Topical application of MSCs could be a safe and 
effective method for the treatment of DES
Reza et al[73], 2011 LSCs Animals Transplantation of a bioengineered CLEC-muc 
sheet in limbal stem cell-deficient rabbit eyes 
resulted in regeneration of a smooth, clear corneal 
surface
Nishida et al[76], 2004 Oral mucosal stem cells Humans Complete reepithelialization of the corneal 
surfaces occurred within 1 wk in all four treated 
eyes. Corneal transparency was restored and 
postoperative visual acuity improved
Corneal stroma and 
endothelium
Sepsakos et al[79], 2017 Ocular surface SCs Humans Without addressing the underlying stem cell 
deficiency, keratoplasty in patients with total 
limbal stem cell deficiency will ultimately fail in 
all cases
Naylor et al[81], 2016 iPSCs Humans The hiPSC-derived NCCs acquired a keratocyte-
like morphology and an expression profile similar 
to corneal keratocytes in vivo
Safety of corneal stromal transplantation of 
autologous ASCs in humans, showing cell 
Alió Del Barrio et al[84], 
2017
ASCs Humans
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survival in vivo and the ability of these cells to 




UC-MSCs Animals UC-MSCs transplantation may be a feasible 
alternative to keratoplasty in treating congenital 
disorders of the cornea secondary to keratocyte 
dysfunction
Yam et al[88], 2018 Perodontal ligament SCs Animals Potential translation of PDL cells for regenerative 
corneal cell therapy for corneal opacities
Joyce et al[89], 2012 UC-MSCs Animals UCB MSCs are able to "home" to areas of injured 
corneal endothelium and that the phenotype of 
UCB MSCs can be altered toward that of HCEC-
like cells
Trabecular meshwork Abu-Hassan et al[93], 
2015
iPSCs Animals TM-like iPSCs became similar to TM cells in both 
morphology and expression patterns. When 
transplanted, they were able to fully restore 
intraocular pressure homeostatic function
Manuguerra-Gagné
et al[95], 2013
MSCs Animals MSC and their secreted factors induced 
reactivation of a progenitor cell pool found in the 
ciliary body and increased cellular proliferation
Lens Lin et al[96], 2016 LECs Both Surgical method of cataract removal that 
preserves endogenous LECs and achieves 
functional lens regeneration in rabbits and 
macaques, as well as in human infants with 
cataracts
Murphy et al[98], 2018 PSCs Animals We demonstrate large-scale production of light-
focusing human micro-lenses from spheroidal 
masses of human lens epithelial cells purified 
from differentiating pluripotent stem cells
ON Kuwahara et al[102], 2015 hESCs Animals Multipotent stem cells within the CM contribute 
to de novo retinal tissue growth
Mesentier-Louro 
et al[105], 2019
iPSCs Animals Between 1% and 7% of iPSCs-derived RGCs 
integrated into the ganglion cell layer after 
intravitreal injection, and about 20% after 
combined injection of RGCs and iPSCs
Zhang et al[107], 2015 UC-MSCs Animals Human umbilical cord blood stem cells and brain-
derived neurotrophic factor effectively repair the 
injured optical nerve, improve biomechanical 
properties, and contribute to the recovery after 
injury
ASC: Adipose-derived stem cell; BM-MSC: Bone marrow-mesenchymal stem cell; CLEs: Cutaneous lupus erythematosus; CM: Ciliary margin; DES: 
Discrete event simulation; HCEC: Human corneal endothelial cell; hESCs: Human embryonic stem cells; hiPSC: Human-induced pluripotent stem cells; 
iPSC: induced pluripotent stem cell; KLAL: Keratolimbal allograft; LEC: Lens epithelial stem/progenitor cell; LSC: Limbal stem cell; MSC: Mesenchymal 
stem cell; NCC: Neurocysticercosis; ON: Optic nerve; PDL: Periodontal ligament; PSC: Pluripotent stem cell; RGC: Retinal ganglion cell; TM: Trabecular 
meshwork; UC-MSCs: Umbilical cord-mesenchymal stem cell; UCB: Umbilical cord blood.
cells by cellular genetic reprogramming using defined transcription factors[8]. First 
described in 2007 by Takahashi et al[19], iPSCs used in the experiments were derived 
from skin fibroblasts produced using retroviral technology[19]. iPSCs provide a 
unique in vitro model that allows the generation of retinal progenitor cells. An 
advantage of iPSCs made from a patient’s own cells could reduce the need for 
immunoprotective regimens post-transplantation[15]. It has been demonstrated that 
these iPSCs have similar characteristics features of PSCs, conserving the possibility to 
generate tissues from each of the three germ layers[20]. The greatest problem reported 
regarding iPSCs was genomic instability, which may induce teratoma. The aim of 
research in recent years has been to create safety protocols capable of guaranteeing 
genomic stability[21]. The greatest success of hPSCs has been in retinal pigment 
epithelial cell (RPE)/photoreceptor replacement for aged-related macular 
degeneration (AMD), but studies have also reported the potential successful use in 
almost all structures of the eye[22,23].
Adult stem cells: The use of adult stem cells represents an easier route to regenerative-
cell therapies. The ability of some adult tissues (i.e. skin, haemopoietic system, bone, 
liver, etc.) to repair or renew, indicates the presence of stem or progenitor cells[9]. 
Numerous clinical trials based on the use of adult stem cells have also been developed 
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In animals or 
in humans     
   
Conclusions
Retina Van Meurs 
et al[109], 2004




iPSCs Animals Adult fibroblast-derived iPSCs provide a viable source for the production of 




hESCs Animals hES cell derived retinal progenitors integrate with the degenerated mouse retina 
and increase in their expression of photoreceptor-specific markers
Nakano 
et al[48], 2012





ESCs Animals We show that rod precursors integrate within degenerate retinas of adult mice 
and mature into outer segment-bearing photoreceptors
Schwartz 
et al[40], 2015
hESCs Humans First evidence of the medium-term to long-term safety, graft survival, and possible 




hESCs Humans The hESC-derived RPE cells showed no signs of hyperproliferation, 





Humans The paracrine nature of adipose stem cells, in particular, has been highlighted as a 
potential solution to the lack of a homing and conducive environment that poses a 
challenge to the implantation of exogenous stem cells in the target tissue
hESCs: Human embryonic stem cells; iPSC: induced pluripotent stem cell; RPE: Retinal pigment epithelium.
in the field of ophthalmology.
Considering that the component of the eye, mainly the retina, is directly derived 
from the central nervous system (CNS), studies regarding cell therapy have shown to 
be difficult, limiting, yet potentially fascinating. The nervous system was thought to be 
rigidly constructed, with no capacity for physical repair. However, studies of nerve 
development have led to isolation of cells from the developing and mature 
mammalian CNS that shows numerous properties of stem cells [neural stem cells 
(NSCs)][9]. NSCs have been studied with success in spinal cord injury and traumatic 
brain injury[24]. NSCs secrete trophic factors, and therapies involving these cells may 
have potential for the neuroprotection of photoreceptors rather than replacement of 
retinal neurons, including retinal ganglion cells (RGC)[22,25].
Bone marrow stem cells (BMSCs) are progenitors of bone, cartilage and skeletal 
tissues, in addition to the hematopoiesis-supporting stroma and adipocyte cells. These 
cells can differentiate into mesenchymal cells, visceral mesoderm, neuroectoderm and 
endoderm characteristics in vitro[26]. In ophthalmology, BMSCs can be used to prevent 
graft vs host disease in corneal transplantation. These cells have also been studied in 
retinal diseases. The rationale for exploring the use of BMSCs as a potential therapy is 
a paracrine trophic effect on degenerating ischemic retina[22,27].
The previous view of adult stem cells has been that the differentiation potential was 
strictly limited to cell lineages found within the tissue of origin studied in tissues such 
as skin and bone marrow. During the past few years, this view has changed. Several 
studies have shown apparent plasticity of adult stem cells, like the ability to differ-
entiate to cell types other than the tissue of origin[9]. This remarkable finding 
challenged the long-held assumption that truly multipotent or pluripotent stem cells 
did not persist beyond early stages in embryogenesis.
Multipotent stem cells can be inserted in this context because they express markers 
of pluripotency previously seen only in ESCs or pregastrulation embryos[9]. The most 
commonly studied multipotent SCs in ophthalmopathies are MSCs. MSCs are 
classically the “post-natal, self-renewing and multipotent stem cells giving rise to all 
skeletal tissues”[2]. They have been found in different fetal tissues, in extraembryonic 
tissues [placenta, umbilical cord (UC) and amniotic fluid] and in adult tissues (bone 
marrow, peripheral blood, adipose tissue, dermis, synovium, periosteoum, cartilage, 
skeletal muscle, fallopian tubes, menstrual blood, gingiva and dental tissue and 
eye)[28]. Placental and adipose-derived MSCs are, by far, considered in the largest 
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Figure 1 The selection of PubMed literature published from 2000 to 2020, which was considered in the manuscript.
number of clinical trials.
Fetal MSCs are scarcely considered in reported studies probably due to the 
difficulties in achieving sufficient cell numbers after expansion[29].
UC-MSCs have excellent proliferation and differentiation properties. These cells are 
readily available in large quantities and cultured rapidly. Moreover, UC incorporates 
both mesenchymal and epithelial stem cells with anti-inflammatory and immune-
privilege properties that can be differentiated into corneal epithelial, stromal and 
endothelial cells[29].
Human adipose-derived stem cells (ASCs) are an easily accessible autologous stem 
cell source. They have been shown to support the growth of many types of stem cells 
including human embryonic stem cells (hESCs), iPSCs and limbal stem cells 
(LSCs)[30]. ASCs resemble BMSCs in terms of morphology, proliferation and 
multipotency[31]. These cells have been considered for various ocular disorders, from 
retinal degeneration (neuroprotection and neurogenesis)[22,31] to corneal dise-
ases[1,3,32].
Dental pulp stem cells (DPSCs) were the first human dental stem cells isolated from 
the dental pulp of permanent teeth[33]. These cells show the unique characteristic of 
the potential to differentiate into not only typical mesodermal cell lineages but also 
ectodermal and endodermal cell lineages. DPSCs have exhibited the potential to differ-
entiate into active neurons, cardiomyocytes, myocytes, melanocytes and hepatocyte-
like cells. These cells have shown higher angiogenic, neurogenic and regenerative 
potential when compared to BMSCs. In the field of ophthalmology, these cells have 
been studied for corneal repair[34], treatment of glaucoma and retinal diseases[35].
Going even more specifically, let us analyze the eye structure. Within the healthy 
eye, different types of adult stem cells can be found, which can be considered as eye 
stem cells. Retinal pigment epithelium stem cells (RPESCs) represent one of the latest 
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discoveries in terms of stem cells of the eye. Retinal epithelium arises from the CNS 
neuro-epithelium. Interestingly, studies have shown how these cells can proliferate in 
some animal species and in certain conditions (e.g., injury). Salero et al[36] identified a 
subpopulation of RPE cells that can be activated to self-renew and that exhibit 
multipotentially, producing either stable RPE progeny or neural, osteo, chondro or 
adipo-lineage mesenchymal progeny[36]. Studies have demonstrated how RPESCs, to 
date unknown, can proliferate pathologically in specific conditions, giving rise to 
retinal disorders. RPESCs are considered as a new type of SC capable of producing 
both CNS and mesoderm-associated lineages[36]. Autologous RPE cell replacement 
has provided proof-of-concept evidence that cell therapy may have promising applic-
ations for retinal degenerative diseases. RPE cell source, however, is restricted for 
applications in RPE cell replacement due to the limited number of donor eyes and 
ethical issues concerning this type of treatment[37].
Hallmark features of the corneal epithelium include the high regenerative potential 
and the capacity for rapid ocular surface repair through proliferation and centripetal 
migration of progenitor cell populations residing at the border of the cornea and the 
sclera in a location called limbus. LSCs represent a quiescent cell population with high 
proliferative potential, which enables efficient corneal regeneration and repair[38]. 
LSCs are fundamental for corneal homeostasis. A loss or deficiency [LSC deficiency 
(LSCD)] of these cells causes the disruption of homeostasis[39]. LSCs can be collected 
using biopsy and expanded in culture, and then they can be transplanted in the 
diseased eye[1].
Criteria for selecting stem cells type: As explained above, stem cells for the treatment 
of ocular disorders can be obtained from the same eye (or fellow eye), from other 
tissues of the patient, or from a donor. As with all treatments, clinicians seek safe, 
widely available and economically viable therapies. Obtaining SCs from the patient’s 
own tissues have changed the therapeutic perspectives. This option has the advantage 
of not requiring immunosuppressive therapies and guarantees no immune 
reactions[40]. Another element that guides the choice of SCs is the availability of cells. 
Alternatives to pluripotent stem and eye tissue cells have been considered in literature, 
however, these options tend to be limiting due to ethical constraints, possible 
unknown adverse effects, little availability and unsustainable costs[21,37]. Autologous 
sources, such as MSCs (UC and adipose stem cells in particular), have been widely 
studied in recent years because of the large availability and the confirmed safety in 
other medical uses[3,4], and seem at the moment to preferential options for the future.
How can stem cells be used in clinical research
Multiple techniques to approach stem cell therapy for ophthalmic disorders have been 
described and studied over time.
Transplantation is the most used technique for stem cell therapy in the eye. SCs can 
be transplanted either as a cell suspension[40] or on different substrates, like 
autologous sheets of cells, biomaterial-based patches or three-dimensional (3D) 
structures[41,42]. SC transplantation is a technique substantially used in all eye 
structures. The key sites currently targeted include: The cornea, mainly the clear tissue 
covering the front of the eye that helps focus the incoming light; the neural retina, 
which contains the photoreceptors; and the RPE, a single layer of pigmented cells that 
plays a key role in maintaining the photoreceptor cells and the blood-retina 
barrier[15,41,42].
Stem cells injection (pluripotent, MSCs or hematopoietic stem cells)[27,40] is a 
procedure still under study today, considered especially for the treatment of AMD. To 
date, these therapies are not yet proven to be safe and effective in ophthalmic use, 
however, have shown to be widely validated in other body districts[43]. Several 
clinical experiments have proposed the injection of SCs into the intravitreal space 
(exploiting the paracrine effect of SCs) or in the subretinal space; however, results 
were not as expected, and several collateral effects have been reported in literature[44] 
that have partially “extinguished” the enthusiasm for results obtained in animal 
clinical trials.
Topical stem cells therapies (eye drops) have been extensively studied to treat 
ocular surface diseases. Hematopoietic stem cells from UC blood serum[45] have been 
proposed for topical treatment of ocular surface diseases. The rationale for applying 
serum to the ocular surface is that, compared to conventional lubricant treatments, it 
more closely resembles natural tears due to several of its biochemical constituents. It 
has produced satisfactory results in terms of efficacy and safety. Moreover, MSCs (in 
particular BMSCs[46] and ASCs[3]) have been used topically for dry eye syndrome or 
other corneal injuries or diseases with promising results. The rationale for MSCs eye 
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drops is the wide-ranging differentiation potential, anti-inflammatory and 
immunomodulatory effects of MSCs[46-49].
In what ocular disorders can stem cells be used
Ocular surface, cornea and limbus: The ocular surface is the interface between the 
functioning eye and the environment. This surface provides anatomic, physiologic and 
immunologic protection and comprises the palpebral and bulbar conjunctival 
epithelium, the corneoscleral limbus, the corneal epithelium and the tear film[50]. The 
functions of ocular surface include maintaining optical clarity of the cornea and 
protection of the structures of the eye from microbes, trauma and toxins. Disorders of 
the ocular surface include a variety of conditions. The most common are dry-eye 
disease, blepharitis, ocular allergies and pterygia. Less common diseases are LSCD and 
ocular surface diseases due to systemic diseases. The narrow zone between cornea and 
bulbar conjunctiva is defined as limbus, which contains layers of cells populated by 
Langerhans cells, melanocytes and LSCs (the stem cells that generate corneal 
epithelium). If a patient has an extensive destruction of the limbus, a functional 
corneal epithelium can no longer be formed, and the cornea reacquires an epithelium 
by invasion of bulbar conjunctival cells. The only way to prevent the corneal 
conjunctivation is indeed to restore the limbus. Keratoplasty has been considered the 
conventional gold standard treatment before the introducing of regenerative 
medicine[51].
The first attempt to restore limbus, using free limbal tissue grafts from the uninjured 
eye, was published by Kenyon and Tseng in 1989[52]. The potential of limbus grafts 
promoted additional studies in this field, which brought the discovery of LSCs[38,53]. 
In 2006, Ma et al[54] showed how transplantation of human MSCs on amniotic 
membrane, like LSCs on amniotic membrane, could reconstruct severely damaged rat 
corneal surface. They demonstrated how the therapeutic effect did not come from 
epithelial differentiation of MSCs but was probably due to the inhibition of inflam-
mation and neovascularization.
Since then, cultures of LSCs have been used to treat corneal diseases and injuries, 
initially engrafting the injured eye from the uninjured one[55], then treating bilateral 
pathologies with expanded cultures of LSCs[56]. The fragility and limited number of 
active SCs of the corneal epithelium in culture, in addition to the induction of 
iatrogenic damage to the healthy fellow eye, however, tend to slow-down and limit the 
clinical application of LSCs. For these reasons, several materials have been proposed to 
enhance results, which include fibrin glue, amniotic membrane, polymers, collagen 
sponges or strips and devitalized membrane or polymers[57].
LSCD is the most challenging disease of the ocular surface for ophthalmologists. 
Corneal LSC grafting procedures have been utilized. This procedure involves either 
direct transplantation of limbal tissue or transplantation of in vitro expanded cells on a 
variety of biological or synthetic carrier materials[29]. These techniques include 
conjunctival limbal autograft, living-related conjunctival allograft[57], keratolimbal 
allograft[58], autologous ex vivo cultivated limbal epithelial transplantation[59], simple 
limbal epithelial transplantation[60], cultivated oral mucosal epithelial trans-
plantation[61] and transplan-tation of peripheral corneal cells[62]. Clinical studies 
using conjunctival limbal autografts have shown excellent short-term and good long-
term results, however, with high risks of complications, which mainly include induced 
damage to the donor eye[63]. For these reason, other types of stem cells have been 
proposed to produce LSCs and corneal epithelium cells.
In 2012, an efficient protocol, with positive preliminary results, was proposed to 
produce corneal epithelial cells from human-iPSCs (hiPSCs)\ESCs obtained from hair 
follicles or dermal fibroblasts[64]. Results were also then confirmed in successive 
studies[65,66]. The evolution of this approach led to the creation of corneal organoids 
from iPSCs[23], initially in two-dimensional, and then in 3D culture systems, with 
promising results as alternative for the treatment of bilateral LSCD[67].
MSCs have also been considered for ocular surface therapy[3,55]. Preliminary 
results in animal experiments are encouraging, and the potential is great. Studies have 
shown how bone marrow-MSCs (BM-MSCs) are safe and can restore corneal epithelia 
from LSCD with the same results of cultivated limbal epithelial transplantation[68]. 
BM-MSC associated with amniotic membranes have successfully been evaluated in 
LSD[69]. Gu et al[70] demonstrated how BM-MSCs could differentiate into cornel 
epithelial like cells in vivo in rat damaged corneas[70]. MSCs have been proposed also 
to promote graft survival[71,72]. This can be explained by the potent immunomodu-
latory properties of SC, suppressing maturation and activation of atrial premature 
complexes and dendritic cells and cytotoxicity of natural killer cells. Several studies 
have attempted to exploit these features of MSCs and have shown interesting results 
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by using topical therapies with eye drops containing MSCs (mainly BM-MSC and 
ASCs)[45,46]. Topical application of MSCs can lead to an increase in aqueous tear 
volume and improvement in ocular surface evaluation tests. Moreover, it is a safe and 
easy applicable method.
Cells derived from epithelial UC-MSCs are capable of forming a stratified epithelial 
layer when seeded on artificial matrices. Reza et al[73] first described the properties of 
UC-MSCs, finding how they have similar characteristics of LSCs[73]. Garzón et al[74] 
utilized an epidermal growth factor enriched medium to induce UC-MSCs to transdif-
ferentiate into corneal epithelial cells on a 3D human artificial anterior cornea 
model[74]. The aim of the use of UC-MSCs derived epithelial cells is to circumvent the 
problem of the limited amount of limbal tissue available for transplantation, especially 
in cases of bilateral LSCD[29].
With regards to MSCs, human immature dental pulp and oral mucosa stem cells 
have been reported to be a promising cell source to correct LSCD, as described by 
Hassan and AbdelAziz[75] and Nishida et al[76]. Studies about ocular surface diseases 
and their treatment are reported in Table 1.
Research is currently searching for new ways of applications of stem cells therapy. 
As described above, MSCs derived exosomes is one of these[28]. The other way 
recently described to facilitate and carry cells to the ocular surface is the use of contact 
lenses[77].
Corneal stroma and endothelium: The corneal stroma is the thickest corneal layer 
(approximately 90% of corneal thickness) and is composed of specialized extracellular 
matrix components and collagen fibrils. Corneal stromal keratinocytes (CSKs) are the 
major cell type in corneal stroma and are located between the collagenous lamellae, 
which are generally quiescent[29]. Corneal insults cause death of CSKs at the injured 
site. Surviving CSKs near the injured site are activated to proliferate, while some 
fibroblasts are induced to transform in highly contractile myofibroblasts. When 
fibroblasts action prevails, scaring and consequent opacity of cornea can occur. The 
presence of dense opacities and persisting scars can interfere with the passage of light 
and cause an important loss of visual acuity if the opacity is large and localized in the 
center of the visual axis of the cornea, thus have an important burden on quality of life 
of patients[78].
Keratoplasty is a primary treatment option and current gold standard to treat 
numerous corneal conditions, including corneal injury, corneal dystrophy, 
keratoconus and corneal infractions. The ever-increasing number of patients needing 
keratoplasty has led to the shortfall of viable donor corneas. Moreover, it is important 
to note that post-surgical complications include important and sight threatening 
conditions, in addition to the risks of transplant rejections and elevated permanently 
induced astigmatism[23]. Sepsakos et al[79] demonstrated that patients who under-
went an ocular surface SCs transplantation (e.g., with LSCs) before keratoplasty have 
better results than patients that did not do that[79].
Various trials (Table 1) trying to obtain keratinocytes derived from hiPSCs have 
been proposed in the past several years[80,81]; however, the genetic reprogramming of 
iPSCs tends to be quite intricate. The differentiation of iPSCs to keratinocytes involves 
two steps[81]. The possibility of obtaining CSKs from iPSCs is very interesting in 
animal models; to date, clinical studies involving injection in humans are lacking in 
literature[82].
MSCs express high levels of hepatocyte growth factor (HGF) in an inflamed 
environment, as is the case in an injured cornea. HGF inhibits the generation of 
opacity-inducing myofibroblasts and, alone, can restore corneal transparency in an in 
vivo model of eye injury[83]. This is the rationale that has been proposed for the use of 
these cells. All MSCs seem to have similar behavior in vivo, being able to achieve 
keratocyte differentiation and modulate the corneal stroma. ASCs have been 
demonstrated to be an ideal source of autologous stem cells, while BM-MSCs have the 
same profile, but the extraction by bone marrow puncture is more complicated, not 
free of risks and painful. A pilot study by del Barrio et al[84] demonstrated the 
apparent safety of corneal stromal transplantation of autologous ASCs in humans, 
showing cell survival in vivo and the ability of these cells to produce a low amount of 
new collagen in patients with advanced keratoconus. Several studies on animals have 
suggested that UC-MSC transplantation may be a feasible alternative to keratoplasty 
in treating congenital disorders of the cornea secondary to keratocyte dysfunction such 
as mucopolysaccharidoses, giving rise to potential future possibilities[85,86]. UC-
MSCs could represent an attractive alternative, but the autologous use of these cells 
tends to be expensive and currently almost impossible.
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An alternative stem cell population currently reported in clinical trials for the 
therapy of corneal stroma disorders include corneal stromal stem cells (CSSCs). These 
cells show similar properties of MSCs and can be obtained by specific cultures of LSCs. 
Experimental studies have shown that CSSCs can differentiate in CSKs after injection 
in the stroma[87].
Periodontal ligament stem cells and DPSCs could differentiate in CSKs and prove to 
be of potential clinical use[28,88].
The corneal endothelium is the posterior corneal surface. It is formed by a 
monolayer of endothelial cells (CECs) that regulate the stromal hydration, preventing 
edema and maintaining corneal deturgescence, which are all fundamental for normal 
vision. These cells are non-mitotic and have limited regenerative capacity. Diseases 
that affect the corneal endothelium cause stromal edema, central opacity and vision 
loss. Full thickness or partial corneal transplantation has been the gold standard for 
endothelial diseases to date; however, preliminary studies have shown that stem cells 
therapies could be of potential clinical use[28,29]. MSCs could serve as a potential 
source to generate corneal endothelial cells for the treatment of corneal endothelial 
diseases, like Fuchs’ endothelial dystrophy and aphakic/pseudophakic bullous 
keratopathy. Joyce et al[89] demonstrated the potential of UC-MSCs to differentiate in 
CECs when treated in particular cultures[89]. At this moment, however, there are no 
concrete data in current literature on the possible application of SCs in human 
endothelial disorders, which remains to be the primary cause of corneal trans-
plantation[29].
Trabecular meshwork: Glaucoma is a degenerative optic neuropathy affecting 
approximately 70 million people worldwide. The most frequent cause of glaucoma is 
the increase of intraocular pressure (IOP) due to an alteration of aqueous outflow. 
Humor aqueous is continuously produced, and its outflow is controlled by the 
trabecular meshwork (TM), an avascular tissue located within the uvea and posterior 
to the corneal margin[90]. TM is populated by specialized cells that decline in number 
with age, and these cells are particularly low in individuals with primary open 
glaucoma. It is probable that TM cells become dysfunctional prior to death and 
increasingly fail to carry out the physiological roles, leading to enhanced aqueous 
humor outflow resistance and the development of pathologically elevated IOP[91]. 
Despite the importance of controlling IOP, the ultimate cause of glaucoma-associated 
vision loss includes axonal damage and the progressive loss of RGCs, the axons of 
retinal neurons that make up the optic nerve and transmit visual information from the 
eye to the brain[91]. The presence of MSCs in TM have been suspected for years and 
then confirmed and propagated in vitro[92].
TM cells are difficult to obtain from a living eye. Studies have faced this problem by 
using iPSCs generated via genetic reprogramming of adult somatic cells[19]. To date, 
the use of TM-like cells derived from iPSCs from a patient’s own dermal fibroblasts 
may offer the best solution to the challenge of TM cell replacement therapy[92]. Abu-
Hassan et al[93] evaluated the results of iPSCs derived TM cell transplantation. The 
study showed that iPSCs differentiate to resemble TM cells in several keyways and 
have the potential to restore the primary TM cell function, thus maintaining IOP 
homeostasis[93].
Recently, other stem cells have been proposed to find the possibility of obtaining 
TM cells (Table 1). MSCs have been used in attempt to repair TM tissue predominantly 
in animals[94]. Kumar et al[31] described the differentiation of ASCs in TM cells[31], 
and Manuguerra-Gagné et al[95] studied the regeneration of TM from BM-MSCs with 
encouraging results[95]. Data in stem cell models are of utmost importance and the 
basis when designing future studies with potential clinical benefits.
Lens: Cataracts are the leading cause of blindness in the world. The current standard 
of care in congenital cataracts involves surgical removal of the cataractous lens and 
implantation of an artificial intraocular lens. Surgery is not free of complications, 
especially in patients with complicated cataracts and with other underlying 
ophthalmic conditions.
Human lens regeneration has not been demonstrated yet, however, lens epithelial 
stem\progenitor cells (LECs) have been isolated[96]. The most significant functions of 
LECs are sustained self-renewal and protective capacities against external 
injuries[97,98]. Li et al[99] have recently reported clinical trials on animals and humans 
(Table 1). They showed that with a new minimally invasive surgical procedure, with 
preservation of LECs, lens regeneration can be achieved with increased visual axis 
transparency and decreased rate of complications. The same conclusion has also been 
reported by Li et al[99]. A further possibility of obtaining lenses through cell differen-
tiation has been proposed by Murphy et al[98], who showed the possibility of creating 
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micro-lenses starting from iPSC differentiation.
Optic nerve
RGCs are a population of CNS neurons located in the innermost layer of the retina and 
convey visual signals from the retina along their axons to the brain. Axonal injury 
leads to the functional loss of RGCs and subsequently induces death of neurons. Axon 
growth is essential for the restoration of neuronal connectivity and reestablishment of 
a functional visual system after optic nerve injury[100]. Some optic neuropathies are 
very common, like glaucoma that is the first cause of irreversible blindness; while 
other conditions tend to be rare. Leber’s hereditary optic neuropathy is just one 
example of this heterogeneous category of ophthalmic pathologies. There is currently 
no treatment available for inherited optic neuropathies such as Leber’s hereditary 
optic neuropathy or dominant optic atrophy. With regards to glaucoma, current 
treatments aim at lowering the IOP. It is well known how the regenerative potential of 
the mammalian CNS is very limited. Research regarding the regeneration of elements 
of the nervous system is thus fascinating and usually limited to animal models.
There are two main objectives of cell therapy, including the delivery of a trophic 
and neuroprotective support[22,27] and (more ambitious) replacement of lost cells and 
functional restoration[101]. The first step in developing cell replacement-based 
strategies for optic nerve regeneration requires a reliable, high-volume source of 
healthy RGCs[102].
iPSCs\ESCs represent the first source studied for the optical nerve regeneration. 
Takahashi et al[19] in 2007 reported a remarkable break-through technology whereby 
adult fibroblasts could be reprogrammed into iPSCs. These transdifferentiated cells 
exhibit similar characteristics to hESCs, including the ability to propagate indefinitely 
and the ability to differentiate into many different cell types, including RGCs. As 
explained by Gokoffski et al[100], there are two different methods for generating RGSs 
from pluripotent stem cells: Organoid differentiation and planar differentiation. 
Organoids are self-organized 3D miniature organs developed in vitro from PSCs. 
Kuwahara et al[102] first developed 3D retinal organoids from hESCs[102]. Planar-
derived RGCs are transdifferentiated from traditional two-dimensional cell culture 
techniques[103,104]. One of the limitations of this technique is the ability of 
iPSCs\ESCs to integrate into the ganglion cell layer. Preliminary results by Mesentier-
Louro et al[105] reported that between 1% to 7% of iPSCs-derived RGCs integrated into 
the ganglion cell layer after intravitreal injection and about 20% after combined 
injection of RGCs and iPSCs[105] (Table 1).
The other limitation regarding the use of iPSCs currently being studied involves the 
possibility of formation of synaptic connections. Axonogenesis of derived RGCs is 
another crucial point: Neurotrophic factors, which theoretically could promote it, keep 
RGCs alive longer. The ideal local cellular environment is essential to permit and 
enhance RGCs in creating new axons; however, neuronal survival does not equate to 
new axon formation[106]. An additional unresolved question involves the possibility 
of new axons in establishing functional synapse.
To overcome the difficulties in integrating RGCs, gene therapy has developed 
possible solutions, which are currently under investigation. Zhang et al[107] 
demonstrated the utility of pigment epithelium-derived factor[107]. It is constitutively 
expressed by various ocular tissues, but its exogenous delivery is therapeutically 
advantageous to promote RGCs survival and axon regeneration. Zhang et al[107] used 
NSCs as cellular vectors to deliver continuously pigment epithelium-derived factor to 
adult retinas after optic nerve injury. These studies showed the utility of genetically 
modified NSCs to protect RGCs and promote axonal regeneration.
The effects of MSCs on RGCs have also been studied (mainly in animals). MSCs 
provide neuroprotection against RGC death; however, studies showed that these SCs 
did not tend to integrate[14]. Preliminary studies by Zhang et al[107] have described 
the possible usefulness of UC-MSCs, which have shown a partial recovery of injured 
optic nerve.
Retina: Visual signalling starts in photoreceptor cells. In the human retina, rods and 
cones are responsible for dim light vision and daylight vision, respectively. Rods are 
located mainly in the peripheral retina, while cones are concentrated in a small portion 
of the retina, called macula. Bipolar cells receive visual signals from photoreceptors 
and transmit it to RGCs. RPE cells form a monolayer underneath the outer segment of 
the photoreceptors, constituting the outer blood-retinal barrier. In the visual system, 
RPE cells play diverse roles, which include absorption of scattered light, regulation of 
nutrients, ions and solutes, secretion of growth factors, regulation of the retinal cycle 
and phagocytosis of photoreceptor outer segment.
Miotti G et al. Stem cell therapy in ocular pathologies 
WJSC https://www.wjgnet.com 378 May 26, 2021 Volume 13 Issue 5
Retinal degenerative diseases are characterized by retinal cell loss, such as RPE 
and/or photoreceptor cell loss in AMD and retinitis pigmentosa, and RGC death in 
glaucoma, as seen previously. Studies that report retinal diseases and treatment are 
summarized in Table 2.
Binder et al[108] and van Meurs et al[109] described the therapeutic potential of 
autologous RPE cells taken from the peripheral region of the retina in AMD. These 
promising results have prompted research towards stem cell therapies to extend it to 
degenerative retinal diseases, where cell replacement is needed[37]. Retinal 
degenerative disorders requiring cell replacement include AMD, retinitis pigmentosa, 
Stargardt’s disease and glaucoma, which represent current challenges in cell therapy. 
RPE cell source is restricted for applications in RPE cell replacement, thus stem cells 
have been studied to solve this limitation.
The greatest potential for cell replacement has been seen with ESC/iPSCs[19], which 
can be successfully pre-differentiated prior to transplantation in the eye, with the 
greatest success shown in RPE/photoreceptor replacement for AMD[22]. Studies 
involving cell reprogramming by Tucker et al[110] and Lamba et al[111] have shown 
the possibility of creating ESC/iPSC-derived retinal progenitors capable of maturing 
in RPE or photoreceptors and capable of integrating in the retina[112]. The same 
results, but with hESCs and hiPSCs, were confirmed by Nakano et al[48] and 
Gonzalez-Cordero et al[113]. The first clinical trials in humans have been done by 
Schwartz et al[40,114] in 2012 and 2015[40,114]: They successfully used hESCs-derived 
RPE cells in Stargardt’s disease without collateral effects (also noted by Mandai 
et al[17]). Cell reprogramming allows the use of autologous PSCs, which guarantee no 
immune reactions with respect to allogenic cells. One of the observed collateral effects 
is the long-term hyperpigmentation of the macula[114]. Potential future alternative 
approaches include the implant of stem cell derived RPE growing on a bioengineered 
scaffold, which can improve stability and maintain cell polarization[14].
Considering the functions of RPE on the overlying retina, it is fundamental to know 
that subretinal RPE transplantation aims at replacing these functions. Transplantation 
of non-RPE cells has been pursued with the rationale that they may counter disease 
through trophic factor secretion. For this reason, clinical trials with subretinal UC-
MSCs, NSCs and retinal progenitor cells are based on trophic support mechanism of 
action. These procedures, however, need further studies considering the potential 
increase of complications[115].
The future of retinal therapies could involve bioengineering. Stern et al[14] have 
reported that incorporating bioengineering approaches may better preserve retinal 
layering and integration in vivo models. The possibilities of this approach have been 
successfully seen in animal clinical trials[116]. Nakano et al[48] has described the 
formation of optic cup and stratified retina from hPSCs. Several successive studies 
have confirmed the possibility of creating retinal organoids and layers of differentiated 
photoreceptors, which can develop outer segment structures[117]. Organoids may 
prove valuable in producing specific retinal cell types or 3D retinal structures for 
transplantation. This is particularly important for conditions such as geographic 
atrophy[14].
An alternative approach to retinal degenerative pathologies with SCs is the 
possibility of exploiting the paracrine capacities of some type of cells. This stem cell 
therapy is not disease specific and can have broad clinical applications, as seen 
previously. This is the potential of BM-MSCs and places them as a candidate cellular 
therapy to combat ocular neurodegeneration, even if these cells are less ideal for 
replacement cell therapy[22,27]. Transplantation of BM-MSCs in experimentally 
induced glaucoma and optic nerve transection show no evidence of the differentiation 
into mature retinal cells (RPE or photoreceptors), despite some integration into the 
retina; but, improvement of retinal function by preserving photoreceptors and RPE cell 
viability have described[118].
ASCs have also been studied for this clinical use, which could prove to be beneficial 
in eye therapies for the paracrine effects, as seen for disorders of the SNC. Several 
studies suggest that ASCs have therapeutic potential for neurodegenerative conditions 
through neurotrophic factor production, with several of the active factors being 
different from those produced by BM-MSCs and DPSCs[27,119]. ASCs and BM-MSCs 
have recently been evaluated with promising results in diabetic retinopathy. ASCs 
have shown the potential to be therapeutically effective in early-stage of diabetic 
retinopathy through paracrine factors and physical contact with endothelial cells[120].
Limits and why not
Stem cell therapy in ocular diseases certainly represents the future in the treatment of 
numerous serious eye diseases, especially if organ transplantation can be avoided. One 
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of the main problems of these therapies, mainly the immunological tolerance to 
transplanted cells, has been solved thanks to the use of autologous cells[17]. Graft vs 
host disease has been limited in this way. Despite all the advantages and promising 
results, what we know about stem cells therapies is still incomplete, especially 
concerning the possible side effects. The tumorigenicity of transplanted stem cells, to 
date, remains to be the most concerning issue for cell transplantation. Advances in 
genetic research and reprogramming have made it possible to reduce the incidence of 
this event[20]. Other side effects may be caused by tissue sampling, particularly if 
performed in the contralateral, healthy eye. This can be avoided using SCs derived 
from other tissues, like ASCs[32].
Stem cell transplantation has the huge limit of the survival and engraftment of cells. 
To improve outcomes, methods considered include pre-treating the host tissue or the 
SCs culture with growth factors or cytokines, embedding SCs in biomaterials or 
expanding SCs in culture. Obtaining an adequate number of SCs is fundamental. For 
example, the expansion of ASCs in culture has been considered, but extensive cultures 
may change the properties of SCs in vivo, rendering them unfit for restoring injured or 
diseased tissues. Genetic research is thus of fundamental importance in this field. A 
further problem related to SCs treatment is the cost of this type of therapy, which is 
still very high today due to limited cost efficient technology to render this therapy 
available on a large scale[37]. Conserving samples of one’s own tissue (i.e. adipose 
stem cells, which are the most represented) taken during other operations, similar to 
the methods used during lipofilling for aesthetic or reconstructive aims, could be a 
possible solution. Moreover, the ethical problem of the use and collection of certain 
cell types, such as ESCs, UC-MSCs and NSCs, remains considerable, which further 
limits SCs use in clinical trials.
Future prospectives
The vast literature and resources used to date underline the importance of stem cell 
therapies, especially for the future. To date, the results are still primordial, but the 
conditions seem leading to an important turning point. Further studies are surely 
needed to provide additional knowledge behind the mysterious physiological and 
potentially curative properties of stem cells, which can pave the way to clinical applic-
ations in ophthalmic care. Numerous current trials have been proposing different 
perspectives for the future of cell therapy in ophthalmic diseases. The therapeutic 
effects of MSCs in regenerative medicine, for example, can also be attributed to 
exosomes, which are secreted soluble factors[45]. Exosomes are extracellular vesicles 
that are produced in the endosomal compartment of most eukaryotic cells and contain 
proteins that regulate tissues biogenesis. Several studies have considered the injection 
of MSCs exosomes in ocular tissues, with interesting results[28]. Research should not 
only be limited at stem cell studies alone but also need to include a whole series of 
innovations brought on by bioengineering and nanotechnology[14,48,118]. Modern 
studies seem to be aimed at the 3D development of fundamental parts of the eye, the 
use of specific vectors that can guarantee the replacing of tissues, and organoids[67]. 
Novel studies are geared at the possibility of reproducing eye tissues in a normal 3D 
configuration. Transplantation of sophisticated multicellular 3D tissues can be an 
exciting opportunity. Nakano et al[48] have shown that hPSCs can generate differen-
tiated 3D structures similar to the embryonic eye cup, containing RPE and neural 
retina. Garzón et al[74] described the generation of the anterior cornea by tissue 
engineering. In addition, bioengineers have proposed to build ocular structures by 
incorporating biocompatible materials with stem cells products, for example to create 
TM or RPE monolayer[47]. Bioengineering is fundamental for the development of 
optimal cell culture biomaterials for the expansion of SCs and the differentiation into 
ocular cells[16]. Modified cultures (e.g., using growth factors, biomaterials, injectable 
hydrogels, scaffolds or membranes containing cells) allow the maturation of cells and 
dedifferentiation, recreating the micro-environment of the host tissue. Consequently, 
there is an easier integration and a better survival of these SCs in the recipient site[42]. 
The advantage of these approaches is to guarantee a reduction of the culture time to 
obtain a viable ocular tissue (such as a cornea[75]), thus avoiding massive tissue 
harvesting (preserving LSCs, for example[75]).
CONCLUSION
The potential therapeutic goals include being able to restore the sense of sight in 
patients who have lost it, by replacing or recreating the damaged eye structures, 
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including restoration of physiological and functional connections with the CNS. Stem 
cell therapies seem to be interesting and promising, even concerning the more external 
structures, including the ocular surface and cornea. Finally, the possibility of using 
these cells topically, without having to subject patients to surgery, organ transplan-
tation or hospitalization, is an element of great importance and hope.
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